These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146 [TBL] [Abstract][Full Text] [Related]
24. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Noble S; Faulds D Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203 [TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis. Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782 [TBL] [Abstract][Full Text] [Related]
26. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients. López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139 [TBL] [Abstract][Full Text] [Related]
27. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523 [TBL] [Abstract][Full Text] [Related]
28. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989 [TBL] [Abstract][Full Text] [Related]
29. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients. Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962 [TBL] [Abstract][Full Text] [Related]
30. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia. Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018 [TBL] [Abstract][Full Text] [Related]
31. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113 [TBL] [Abstract][Full Text] [Related]
33. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression. Shah AP; Chen JM; Fridell JA Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498 [TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707 [TBL] [Abstract][Full Text] [Related]